scholarly journals Ulcerative colitis associated with primary colorectal lymphoma in Taiwan: A tertiary center study

2020 ◽  
Vol 7 (4) ◽  
pp. 195-200
Author(s):  
Cheng‐Lu Lin ◽  
Cheng‐Kuan Lin ◽  
Yew‐Loong Leong ◽  
Chien‐Chih Tung ◽  
Chia‐Tung Shun ◽  
...  

Urolithiasis ◽  
2019 ◽  
Vol 48 (4) ◽  
pp. 305-311 ◽  
Author(s):  
Vidit M. Talati ◽  
Ricardo M. O. Soares ◽  
Aziz Khambati ◽  
Robert B. Nadler ◽  
Kent T. Perry


2013 ◽  
Vol 7 ◽  
pp. S260
Author(s):  
M. Dranga ◽  
C. Mihai ◽  
E. Toader ◽  
G. Dumitrescu ◽  
I. Pintilie ◽  
...  


2015 ◽  
Vol 148 (4) ◽  
pp. S-862
Author(s):  
Sami Evirgen ◽  
Raim Iliaz ◽  
Filiz Akyuz ◽  
Bilger Cavus ◽  
Binnur S. Pinarbasi ◽  
...  


2021 ◽  
Author(s):  
Hatice Mine Cakmak ◽  
Omer Kartal

Abstract Background/Objectives: Propranolol is the mainstay treatment of infantile hemangioma, and the optimal dose is unclear. Few studies are comparing the efficacy of propranolol dose of 2 vs.3 mg/kg/day. We compared the efficacy between these two doses and propranolol groups with no treatment group. Methods: One hundred eight patients with infantile hemangioma (15 days-27 months of age) were examined. The patients with high-risk features and/or a score of >6 points are given propranolol with a final dose of 2 or 3 mg/kg/day according to tolerance for 6-12 months. The resolutions rates for propranolol vs. placebo and propranolol 2 mg/kg/day vs. 3 mg/kg/day are compared. Results: The demographic and clinical features of the groups ( the non-treatment, propranolol 2 mg/kg/day group, propranolol 3 mg/kg/day group) are similar. Propranolol is significantly efficent in infantil hemangioma treatment (p<0.001). The resolution rates are not statistically different between 2 mg/kg/day propranolol group vs 3 mg/kg/day propranolol group at the sixth (68,59 ± 28,95 vs 73,44 ± 32,54)(p=0,673) and twelfth month (p=0,673) (89,08 ± 46,58 vs 91,13 ± 37,46 respectively )of follow up. A milld (n=3)(4%) adverse event was reported with no need for cessation.Conclusions: Propranolol is a safe drug for treating infantile hemangioma with an ideal dose of 2 mg/kg/day rather than 3 mg/kg/day.





2014 ◽  
Vol 8 ◽  
pp. S425
Author(s):  
K. Dimakou ◽  
S. Fessatou ◽  
M. Maragoudaki ◽  
I. Panayotou ◽  
E. Roma-Giannikou ◽  
...  


2010 ◽  
Vol 138 (5) ◽  
pp. S-696
Author(s):  
Nilay Kumar ◽  
Ashwin N. Ananthakrishnan ◽  
Yelena Zadvornova ◽  
Mazen Issa ◽  
Amar S. Naik ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document